Minnelide reduces tumor burden in preclinical models of osteosarcoma
about
Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlightMinnelide: a novel therapeutic that promotes apoptosis in non-small cell lung carcinoma in vivoTriptolide activates unfolded protein response leading to chronic ER stress in pancreatic cancer cells.Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.Triptolide induces apoptotic cell death of human cholangiocarcinoma cells through inhibition of myeloid cell leukemia-1.Up-regulated isocitrate dehydrogenase 1 suppresses proliferation, migration and invasion in osteosarcoma: in vitro and in vivoTriptolide and its prodrug minnelide suppress Hsp70 and inhibit in vivo growth in a xenograft model of mesothelioma.Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity.Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug.Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancerTriptolide enhances the tumoricidal activity of TRAIL against renal cell carcinomaTargeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia.Triptolide abrogates growth of colon cancer and induces cell cycle arrest by inhibiting transcriptional activation of E2F.Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1.Heterotypic mouse models of canine osteosarcoma recapitulate tumor heterogeneity and biological behavior.Heat shock transcription factor 1 promotes the proliferation, migration and invasion of osteosarcoma cells.Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.Minnelide effectively eliminates CD133(+) side population in pancreatic cancer.A Novel Immunocompetent Mouse Model of Pancreatic Cancer with Robust Stroma: a Valuable Tool for Preclinical Evaluation of New Therapies.Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer.CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to MinnelideThe analgesic effects of triptolide in the bone cancer pain rats via inhibiting the upregulation of HDACs in spinal glial cells.Inactivation of cancer-associated-fibroblasts (CAF) disrupts oncogenic signaling in pancreatic cancer cells and promotes its regression.Discovery and optimization of cardenolides inhibiting HSF1 activation in human colon HCT-116 cancer cells.Cellular and Molecular Networking Within the Ecosystem of Cancer Cell Communication via Tunneling Nanotubes
P2860
Q26766075-27A9A696-9D56-4740-8E60-A5B78C6753ECQ27303920-E305B801-17EF-452F-A5D1-55AE3760F8FBQ33701588-A296DB41-D03D-4D25-A597-2110ED5BA6D5Q34502672-168ADF8C-D00F-4220-BB56-1FD5F8838E11Q35151115-0BB7DD7F-D857-4682-A27D-FDA0DE26AA96Q35187955-A2C13CA1-0E3D-44E7-BA1D-4416CA4E958DQ35591904-AEC95E97-6C42-407C-8522-9D7B8493F8E2Q35677567-6081E9C7-6A01-48D8-A8E6-F748694E6D33Q36092073-C36D5C27-B7EB-4A8D-8E68-6067A31A5BE0Q36278712-34057CB8-4073-4DDB-BC31-9D9E41BDDCABQ36470781-7D645454-613D-48AE-8F02-9F558A69039FQ36544683-8895F6A0-FDDA-4126-BAF8-EC8741EEEBBBQ37211609-88FD1305-21BA-4C05-88E8-0E7E7D60C4C0Q37333773-F7226F4E-4B22-4DFA-87D4-863455B4158FQ37545406-6FECB305-1E0B-4920-B25F-CFC00F6BAF8AQ38709198-3319D0C6-F3D3-4591-B567-6C751FE76069Q38718518-37CE9CF7-FEF8-4628-82CC-454BA9CDBFD1Q38817435-4F928AC8-3610-4067-ACD1-0823D589D8C1Q38818544-0B636DF0-A87C-481C-936D-4D32C0962E83Q38832632-0C98D596-97B2-48EF-9BAC-DAF14F67C065Q39014873-8417F77D-D78A-4643-AC30-5338DFAA76A1Q47138089-89CBE91A-CDA2-4522-9673-3213312954DFQ48563861-FB63722F-D807-4EB4-A9D2-F56E28F2A657Q55311846-6A0ED95B-59D2-47E3-981A-FFA89A21D257Q58586127-3CA6148B-3DF0-425E-9590-FF795D4DB82B
P2860
Minnelide reduces tumor burden in preclinical models of osteosarcoma
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Minnelide reduces tumor burden in preclinical models of osteosarcoma
@ast
Minnelide reduces tumor burden in preclinical models of osteosarcoma
@en
type
label
Minnelide reduces tumor burden in preclinical models of osteosarcoma
@ast
Minnelide reduces tumor burden in preclinical models of osteosarcoma
@en
prefLabel
Minnelide reduces tumor burden in preclinical models of osteosarcoma
@ast
Minnelide reduces tumor burden in preclinical models of osteosarcoma
@en
P2093
P2860
P1433
P1476
Minnelide reduces tumor burden in preclinical models of osteosarcoma
@en
P2093
Ashok K Saluja
Sulagna Banerjee
Tiffany N Mackenzie
Veena Sangwan
Venugopal Thayanithy
P2860
P304
P356
10.1016/J.CANLET.2013.02.050
P407
P577
2013-03-14T00:00:00Z